2.28

9.62% 0.20

After Hours: 2.29 0.01 +0.44%

Brainstorm Cell Therapeutics Inc (BCLI)

Overview News Price History Option Chain Financials Why BCLI Down? Discussions Forecast Stock Split

Brainstorm Cell Therapeutics Inc stock is traded at $2.28, with a volume of 182.80K. It is up +9.62% in the last 24 hours and up +80.95% over the past month. Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.

Previous Close:

$2.08

Open:

$2.23

24h Volume:

182.80K

Relative Volume:

1.76

Market Cap:

$13.00M

Revenue:

Net Income/Loss:

$-16.63M

P/E Ratio:

-3.8644

EPS:

-0.59

Net Cash Flow:

$-21.84M

1W Performance:

+57.24%

1M Performance:

+80.95%

6M Performance:

-60.67%

1Y Performance:

-21.69%

1-Day Range:

$2.201

$2.4499

1-Week Range:

$1.42

$2.4499

52-Week Range:

$1.05

$11.89

Brainstorm Cell Therapeutics Inc Stock (BCLI) Company Profile

Name

Brainstorm Cell Therapeutics Inc

Sector

Healthcare (1176)

Industry

Biotechnology (673)

Phone

201-488-0460

Address

1325 AVENUE OF AMERICAS, NEW YORK, NY

Employee

Twitter

@BrainStormCell

Next Earnings Date

2024-11-05

Latest SEC Filings

BCLI's Discussions on Twitter

Compare BCLI with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BCLI Brainstorm Cell Therapeutics Inc	2.28	13.00M	0	-16.63M	-21.84M	-0.43
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Brainstorm Cell Therapeutics Inc Stock (BCLI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-04-21	Upgrade	Maxim Group	Hold → Buy
Nov-17-20	Downgrade	Maxim Group	Buy → Hold
Dec-19-16	Reiterated	Maxim Group	Buy
Dec-22-15	Reiterated	Maxim Group	Buy

Brainstorm Cell Therapeutics Inc Stock (BCLI) Latest News

Dec 12, 2024

BrainStorm Cell Therapeutics to Host Investor Call and Provide a Corporate Update - The Eastern Progress Online

Dec 12, 2024

BrainStorm Cell Therapeutics Announces Presentations on NurOwn® at 2024 Annual NEALS Meeting - The Eastern Progress Online

Dec 12, 2024

Dec 11, 2024

BrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS) on December 11, 2024 - The Eastern Progress Online

Dec 11, 2024

Dec 10, 2024

Amyotrophic Lateral Sclerosis (ALS) Market: Segmentation - openPR

Dec 10, 2024

Dec 09, 2024

BrainStorm Cell Therapeutics Announces Major ALS Treatment Webinar with Leading Expert - StockTitan

Dec 09, 2024

Dec 07, 2024

BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - Kilgore News Herald

Dec 07, 2024

Dec 06, 2024

Autologous Cell Therapy Market Expected to Grow at Rapid Rates - openPR

Dec 06, 2024

Dec 04, 2024

BrainStorm secures patent for exosome technology By Investing.com - Investing.com Nigeria

Dec 04, 2024

BrainStorm Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology - Lelezard

Dec 04, 2024

Dec 03, 2024

BrainStorm secures patent for exosome technology - Investing.com

Dec 03, 2024

Brainstorm Cell Therapeutics Inc. Strengthens Exosome Patent Portfolio; Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology - Marketscreener.com

Dec 03, 2024

Breakthrough Patent Propels BrainStorm’s Next-Gen Therapies - Smartphone Magazine

Dec 03, 2024

Dec 01, 2024

BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing - Marketscreener.com

Dec 01, 2024

Nov 29, 2024

Gene and Cell Therapies Targeting CNS Disorders Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight - The Globe and Mail

Nov 29, 2024

Gene and Cell Therapies Targeting CNS Disorders Treatment - openPR

Nov 29, 2024

Nov 22, 2024

BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Mini - GuruFocus.com

Nov 22, 2024

Nov 21, 2024

Brainstorm Cell Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 21, 2024

Nov 18, 2024

Stem Cell Therapy Market to Reach $19.1 Billion by 2031 | Advanced - openPR

Nov 18, 2024

Nov 15, 2024